Factors that contribute to the recurrence of mucinous ovarian cancer: Monocenter retrospective evaluation.

IF 1.4 4区 医学 Q4 ONCOLOGY Journal of cancer research and therapeutics Pub Date : 2023-04-01 DOI:10.4103/jcrt.jcrt_109_21
Ozer Birge, Mehmet Sait Bakır, Ceyda Karadag, Selen Doğan, Hasan Aykut Tuncer, Tayup Simsek
{"title":"Factors that contribute to the recurrence of mucinous ovarian cancer: Monocenter retrospective evaluation.","authors":"Ozer Birge,&nbsp;Mehmet Sait Bakır,&nbsp;Ceyda Karadag,&nbsp;Selen Doğan,&nbsp;Hasan Aykut Tuncer,&nbsp;Tayup Simsek","doi":"10.4103/jcrt.jcrt_109_21","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>In this study, we aimed to put forth the factors that contribute to the recurrence of mucinous ovarian cancer.</p><p><strong>Materials and methods: </strong>Forty-four mucinous ovarian cancer patients who have presented to our clinic between February 2006 and May 2018 took part in the study. In order to predict the factors that contribute to recurrence, the univariate and the multivariate logistic regressions were utilized. The Kaplan-Meier survival analysis was utilized for survival and the log-rank test was used for the discrepancies between the groups. In the analysis of the data, the Statistical Package for the Social Sciences 22 program was used. It was acknowledged to have statistical meaning when the P value in all the tests was lower than 0.05.</p><p><strong>Findings: </strong>Recurrence was detected in 20 out of 44 patients who participated in the study. The ages of the patients who did not experience recurrence were significantly lower ( P = 0.001). The patients were detected mostly in Stage 1 (36.4%). In the group of patients without recurrence, systemic lymphadenectomy (43.2%) was greater ( P = 0.019). Lymph node metastasis was three times higher in the group that experienced recurrence ( P = 0.047). When the two groups were compared, the platinum resistance was considerably greater in the group with recurrence ( P = 0.005). In terms of residual tumor, the rate of complete resection was (9%) better in the group that experienced recurrence compared to the group that did not experience recurrence, with a rate of 45.5%. While 12 patients who experienced recurrence died, 6 people died in the other group. From the factors that contribute to recurrence, in terms of residual tumor quantity, this was grouped as complete (R0) resection and optimal + suboptimal (R1 + R2) resection and the following were determined: odds ratio (OR) - 5.7 (95% confidence interval [CI]: 1.56-20.9) and P = 0.008 for R1 + R2. In univariate analysis, the OR was determined as 1.16 (95% CI: 1.06-1.27) for age. Possessing a Stage 2 and higher disease statistically contributed considerably to the recurrence compared to Stage 1 disease (OR: 6.33; 95% CI: 1.59-25.22; P = 0.009). Age was determined as an independent prognostic risk factor in the multivariate analysis (OR: 1.10 [95% CI: 1.04-1.25]), P = 0.018. Furthermore, the OR for the advanced-stage (Stage 2 or higher) patients in the multivariate analysis was determined as 7.88 (95% CI: 0.78-78.8) and was found to be statistically significant at limits ( P = 0.079).</p><p><strong>Results: </strong>We have put forth that the genetic, biological, and clinical characteristics of mucinous ovarian cancers differ from that of other epithelial ovarian cancers, and that age, advanced stage, and residual tumor quantity are prognostic risk factors in terms of recurrence, and that age is an independent prognostic risk factor.</p><p><strong>Conclusion: </strong>Biological and clinical characteristics of mucinous ovarian cancers differ from those of other epithelial ovarian cancers, and we observed that the age, advanced stage, and the amount of residual tumor regarding recurrence are prognostic risk factors, while age was determined as an independent prognostic risk factor.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 3","pages":"610-616"},"PeriodicalIF":1.4000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/jcrt.jcrt_109_21","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: In this study, we aimed to put forth the factors that contribute to the recurrence of mucinous ovarian cancer.

Materials and methods: Forty-four mucinous ovarian cancer patients who have presented to our clinic between February 2006 and May 2018 took part in the study. In order to predict the factors that contribute to recurrence, the univariate and the multivariate logistic regressions were utilized. The Kaplan-Meier survival analysis was utilized for survival and the log-rank test was used for the discrepancies between the groups. In the analysis of the data, the Statistical Package for the Social Sciences 22 program was used. It was acknowledged to have statistical meaning when the P value in all the tests was lower than 0.05.

Findings: Recurrence was detected in 20 out of 44 patients who participated in the study. The ages of the patients who did not experience recurrence were significantly lower ( P = 0.001). The patients were detected mostly in Stage 1 (36.4%). In the group of patients without recurrence, systemic lymphadenectomy (43.2%) was greater ( P = 0.019). Lymph node metastasis was three times higher in the group that experienced recurrence ( P = 0.047). When the two groups were compared, the platinum resistance was considerably greater in the group with recurrence ( P = 0.005). In terms of residual tumor, the rate of complete resection was (9%) better in the group that experienced recurrence compared to the group that did not experience recurrence, with a rate of 45.5%. While 12 patients who experienced recurrence died, 6 people died in the other group. From the factors that contribute to recurrence, in terms of residual tumor quantity, this was grouped as complete (R0) resection and optimal + suboptimal (R1 + R2) resection and the following were determined: odds ratio (OR) - 5.7 (95% confidence interval [CI]: 1.56-20.9) and P = 0.008 for R1 + R2. In univariate analysis, the OR was determined as 1.16 (95% CI: 1.06-1.27) for age. Possessing a Stage 2 and higher disease statistically contributed considerably to the recurrence compared to Stage 1 disease (OR: 6.33; 95% CI: 1.59-25.22; P = 0.009). Age was determined as an independent prognostic risk factor in the multivariate analysis (OR: 1.10 [95% CI: 1.04-1.25]), P = 0.018. Furthermore, the OR for the advanced-stage (Stage 2 or higher) patients in the multivariate analysis was determined as 7.88 (95% CI: 0.78-78.8) and was found to be statistically significant at limits ( P = 0.079).

Results: We have put forth that the genetic, biological, and clinical characteristics of mucinous ovarian cancers differ from that of other epithelial ovarian cancers, and that age, advanced stage, and residual tumor quantity are prognostic risk factors in terms of recurrence, and that age is an independent prognostic risk factor.

Conclusion: Biological and clinical characteristics of mucinous ovarian cancers differ from those of other epithelial ovarian cancers, and we observed that the age, advanced stage, and the amount of residual tumor regarding recurrence are prognostic risk factors, while age was determined as an independent prognostic risk factor.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
导致癌症黏液性复发的因素:单核回顾性评价。
目的:本研究旨在探讨癌症黏液性肿瘤复发的因素。材料和方法:在2006年2月至2018年5月期间,共有44名癌症黏液性患者参加了本研究。为了预测导致复发的因素,使用了单变量和多变量逻辑回归。Kaplan-Meier生存率分析用于生存率,对数秩检验用于组间差异。在数据分析中,使用了社会科学22计划的统计包。当所有测试中的P值低于0.05时,这被认为具有统计学意义。结果:在参与研究的44名患者中,有20名患者检测到复发。未复发患者的年龄明显较低(P=0.001)。患者大多在1期(36.4%)被发现。在未复发的患者组中,全身淋巴结清扫术(43.2%)更大(P=0.019)。淋巴结转移在复发的患者中高出三倍(P=0.047)。当比较两组时,复发组的铂耐药性明显更高(P=0.005)。就残留肿瘤而言,复发组的完全切除率(9%)高于未复发组,为45.5%。12名复发患者死亡,另一组有6人死亡。根据导致复发的因素,就残留肿瘤数量而言,这被分为完全(R0)切除和最佳+次优(R1+R2)切除,并确定以下因素:比值比(OR)-5.7(95%置信区间[CI]:1.56-20.9),R1+R2的P=0.008。在单因素分析中,年龄的OR为1.16(95%CI:1.06-12.7)。与1期疾病相比,患有2期及以上疾病在统计学上对复发有很大贡献(OR:6.33;95%CI:1.59-25.22;P=0.009)。在多变量分析中,年龄被确定为独立的预后风险因素(OR:1.10[95%CI:1.04-12.5]),P=0.018。此外,在多变量分析中,晚期(2期或更高阶段)患者的OR被确定为7.88(95%CI:0.78-78.8),并被发现具有统计学意义(P=0.079)。结果:我们已经提出,粘液性卵巢癌的遗传、生物学和临床特征与其他上皮性卵巢癌不同,晚期和残留肿瘤数量是复发的预后风险因素,而年龄是独立的预后风险因子。结论:黏液性卵巢癌的生物学和临床特征与其他上皮性卵巢癌不同,我们观察到年龄、晚期和复发时残留肿瘤的数量是预后的危险因素,而年龄被确定为独立的预后危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.80
自引率
15.40%
发文量
299
审稿时长
6 months
期刊介绍: The journal will cover technical and clinical studies related to health, ethical and social issues in field of Medical oncology, radiation oncology, medical imaging, radiation protection, non-ionising radiation, radiobiology. Articles with clinical interest and implications will be given preference.
期刊最新文献
Evaluation of response to neoadjuvant chemotherapy in technically unresectable moderately advanced oral cavity cancers Gastrointestinal bleeding due to obstruction of the superior mesenteric vein Microwave ablation combined with percutaneous vertebroplasty for treating painful non-small cell lung cancer with spinal metastases under real-time temperature monitoring Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis Sexual function status after adjuvant radiation including vaginal cuff brachytherapy in survivors of cancer cervix
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1